Your provider starts you low, raises the dose gradually, and checks in monthly so anything uncomfortable is addressed early
The medication works the same regardless of which approved site you choose
Accordingly, the bulk of the clinical evidence of the effects of the drug class on HF have been collected in the placebo-controlled CVOTs in people with type 2 diabetes and established CVD or CVD risk (Table 1) (Pfeffer et al., 2015
The SELECT Trial Participant profile: 17,604 participants who were all over 45, had a body-mass index (BMI) of 27 or above, did not have diabetes, and had established cardiovascular disease, such as a prior heart attack or stroke
Well, the existing data do not show that. Patients often stop using GLP-1s within a year for a variety of reasons, including cost, meeting their goal weight or gastrointestinal side effects
These medications are designed to be similar to the endogenous incretin GLP-1 but with longer-lasting and more potent effects